Celerion is a member of the UK’s Translational Research Partnership in Respiratory. The membership of Celerion’s Belfast facility within the UK’s Translational Research Partnership in Respiratory enables faster access to target patient populations, specialists and techniques in Phase I & IIa studies. Clients benefit from faster access to data that expedites decision making and speeds up the path to clinical Proof-of-Concept (POC).
This membership offers our clients, a one stop solution for respiratory studies. This enables Celerion to work with key decision makers and thought leaders in the UK to develop and execute Phase I and II studies with targeted patient populations.
The collaboration provides access to patients suffering from asthma, COPD, cystic fibrosis, bronchiectasis and interstitial lung disease. Celerion also has access to:
- Laboratory capabilities – Flow cytometry, flow cytometric cell sorting, microbiology, 16S, deep sequencing, MLST, transcriptomics
- Lung imaging techniques – CT acquisition of images, dedicated MRI time, advanced CT analysis capabilities and MRI acquisition of images
- Challenge Models – Allergen, LPS, AMP
- Bronchoalveolar Lavage
The UK’s Translational Research Partnership in Respiratory is a unique cooperative of internationally leading clinicians and scientists whose aim is to improve the speed of developing innovative therapies for respiratory diseases by working in collaboration with research groups of the pharmaceutical industry. They have been recognized for their excellence in basic and translational research in respiratory medicine.